Methods of monitoring responsiveness to anti-SMAD7 therapy
AssigneeNogra Pharma Limited
InventorsGiovanni Monteleone, Francesca Viti, Salvatore Bellinvia
Life of this patent
Estimating the term…
Abstract
Methods for monitoring whether a subject will be sensitive or resistant to treatment with an anti-SMAD7 therapy are disclosed. The methods are based on the determining of the amount of CCR9+ FOXP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FOXP3+ T cells, IFN-gamma+ T cells, and/or IL17A+ T cells in a sample from the subject. Measurement of T cell populations may be determined by flow cytometry, immunohistochemistry, and/or ELISA.
Claims24
A method of treating Inflammatory Bowel Disease (IBD) in a subject in need thereof, the method comprising administering an anti-SMAD7 therapy to a subject who has been
- determined to have an increased amount of a cell population of CCR9+ FoxP3+ cells, and/or a decreased amount of at least one cell population selected from the group consisting of CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FoxP3+ T cells, IFN-gamma+ T cells, and IL17A+ T cells, relative to a known control level of the corresponding cell population, in response to administration of the anti-SMAD7 therapy.
A method of treating Inflammatory Bowel Disease (IBD) in a subject in need thereof, the method comprising:
- administering to the subject an anti-SMAD7 therapy;
- determining the amount of at least one cell population selected from the group consisting of:
- CCR9+ FoxP3+ T cells, CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FoxP3+ T cells, IFN-gamma+ T cells, and IL17A+ T cells in a sample from the subject;
- and,
- if after the administering step the subject is determined to have an increase in the amount of the cell population of CCR9+ FoxP3+ cells, and/or a decrease in the amount of at least one of the cell populations of CCR9+ IFN-gamma+ T cells, CCR9+ IL17A+ T cells, FoxP3+ T cells, IFN-gamma+ T cells, and IL17A+ T cells, in at least one sample obtained from the subject relative to a known control level of the corresponding cell population, then continuing the anti-SMAD7 therapy.
Dependencies are inferred from the claim text.